Novo Nordisk CEO Says Obesity Drug Market Won’t Be Winner-Take-All — BigGo Finance
Novo Nordisk (NVO) CEO Mike Doustdar pushed back Wednesday against the prevailing investor narrative that the booming obesity…
Novo Nordisk announces strategic partnership with AWS. Will it be enough to turn around its financial performance?
After kickstarting the GLP-1 wave that transformed the pharma landscape and briefly sending its market value above Denmark’s…
Novo Nordisk CFO Knudsen: Oral Wegovy Drives Market Expansion With 80% of Patients New to Obesity Drugs — BigGo Finance
Novo Nordisk delivered what CFO Karsten Munk Knudsen called “one of the bigger guidance hikes we’ve had as…
![[NVO Q2 2026 Earnings Call] Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with 300k Patients](https://www.europesays.com/dk/wp-content/uploads/2026/08/aHR0cHM6Ly9pbWcuYmdvLm9uZS9uZXdzLWltYWdlL2Vhcm5pbmdzX2NhcmQvMjAyNi0wOC9VU19OVk9fMjAyNi0wOC0wNV8xNzg1-380x220.jpeg)
[NVO Q2 2026 Earnings Call] Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with 300k Patients
Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with…
Novo Nordisk’s Two-Stage Catalyst: Earnings Due August 5 as CagriSema FDA Verdict Hovers
Novo Nordisk is entering a defining stretch of the year, with two pivotal events that could reshape the…
Novo Nordisk Gets Hemophilia Boost as CagriSema Device Pause Stays in the Background
Novo Nordisk shares are staging a recovery from March’s 52-week trough, supported by encouraging late-stage hemophilia data and…
Novo Nordisk Forges Ahead with Oral Wegovy and Weekly Insulin Amid CagriSema Device Study Withdrawal
Novo Nordisk is executing a multi-front strategy to defend its dominance in the obesity and diabetes markets, rolling…
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
In the air-conditioned haven of the Hilton just downriver from the American Diabetes Association’s 2026 Scientific Sessions in…
‘No change’ for CagriSema as Novo ditches single-chamber device
Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the…
Novo Nordisk’s CagriSema Advances as Data Breach Tests Investor Confidence
Novo Nordisk finds itself navigating two starkly different narratives this week. On one hand, the Danish pharma giant…
Novo Nordisk: Zenagamtide and Etavopivat Shine, but the Market Only Sees CagriSema
Novo Nordisk’s shares continue to trade under a dark cloud, down roughly 46% over the past twelve months…
ADA: Novo CSO says ‘jury still out’ on CagriSema v. retatrutide
Even as industry watchers pit the two obesity assets against one another, it’s too early to say whose…